Research programme: cervical cancer therapy - KuDOS
Latest Information Update: 22 Jan 2008
Price :
$50 *
At a glance
- Originator KuDOS Pharmaceuticals
- Developer KuDOS Pharmaceuticals; MerLion Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cervical cancer; Human papillomavirus infections
Most Recent Events
- 17 May 2005 This programme is still in active development
- 04 Apr 2003 Preclinical trials in Cervical cancer in Singapore (unspecified route)
- 04 Apr 2003 Preclinical trials in Human papillomavirus infections in Singapore (unspecified route)